No Prescription |
 |
 | ||
|
Prax Effient |
|
| ||
No Prescription » Prescription Drugs 13 » Prax Effient Prax is indicated to help and reduce the risk of a future heart-related event such as a heart attack or silent clot in patients who had an acute coronary syndrome (ACS) event that was treated with angioplasty. Buy Prax Effient and other Prescription Drugs 13 products online at Medstore. Buy Online at Medstore - Click Here!
About Prax Effient: Product Type: Prescription Drugs 13 Prax ( Effient Efient ) Prax (Effient Efient) Effient Efient 10mg 100 Tablets 10mg 200(2 x 100) Tablets 10mg 400(4 x 100) Tablets 5mg 100 Tablets 5mg 200(2 x 100) Tablets 5mg 400(4 x 100) Tablets Effient Efient Prax
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
